Clinical Trial Update: Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride [Phase 2]

View source ↗

Summary

A Phase 2 patient-preference study comparing standard of care versus once-daily trientine tetrahydrochloride for Wilson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wilson Disease

Drugs mentioned

• Trientine tetrahydrochloride (trientine tetrahydrochloride)

Snippet

Sponsor: Orphalan | Conditions: Wilson's Disease | Phase 2 | Status: COMPLETED